No | Age | Sex | Onset or relaps | Lung involvemen | Cr before / after RTX (umol/L) | Alb before / after RTX (g/L) | Urine protein before / after RTX (g/d) | ANCA titer before / after RTX (U/ml) | BVAS before/after RTX | CD19 + B cells Before / 1 months after X (/μL) | Corticosteroids, PE and IVIG | Follow-up period | SAEs during the follow-up period |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 68 | F | Onset | No | 188.0 /97.7 | 23.0 / 34.9 | 8.9 / 0.13 | Anti-MPO, 86 / neg | 17/0 | 204/16 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX, No PE or IVIG | 1 year | none |
2 | 63 | F | Onset | No | 838.4 / 113.7 | 25.0 / 44.0 | 2.7 /0.09 | Anti-MPO, 49 / neg | 14/0 | 333/5 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX. No PE.IVIG for 20 g*5d, twice | 1 year | none |
3 | 67 | M | Onset | No | 443.9 / 146.7 | 27.7 / 39.5 | 1.05 / 0.40 | Anti-MPO, 43 / neg | 25/12 | 302/3 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX.PE for 5 times.IVIG for 20 g*5d | 1 year | none |
4 | 59 | M | Relapse | alveolar hemorrhage | 182.4 / 295.0 | 32.7 / 27.7 | 4.04 / 1.95 | Anti-MPO, 55 / 76 (relapsed again at 11 months after RTX) | 20/18 | 137/0 | P 10 mg/d. PE for 5 times. No IVIG | 1 year | Curable pneumonia at 11 months after RTX |
5 | 75 | F | Onset | NO | 565.2 / 243.0 | 30.4 / 45.9 | 1.37 / 0.286 | Anti-MPO, 136, neg | 14/12 | 455/2 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX. No PE. IVIG for 20 g*5d | 1 year | none |
6 | 70 | F | Relapse | NO | 162.8 / 157.1 | 21.0 / 34.0 | 0.74 / 2.98 | Anti-MPO, > 200, neg | 18/12 | 709/2 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX. No PE or IVIG | 1 year | none |
7 | 32 | M | Onset | Pulmonary consolidation | 159.3 / 89.3 | 28.6 / 48.1 | 2.58 / 0.27 | Anti-MPO, 100, 27 | 19/4 | 315/3 | MP 500 mg*3. P 1 mg/kg before RTX; 0.5 mg/kg from RTX. No PE or IVIG | 6 months | none |
8 | 58 | F | Onset | Interstitial Pneumonitis | 347.7 / 124.5 | 33.2 / 45.1 | 1.07 / 0.09 | Anti-MPO, 136, neg | 13/8 | NA/0 | P 1 mg/kg before RTX; 0.5 mg/kg from RTX. PE for 6 times. No IVIG | 6 months | none |